Achillion Pharmaceuticals Inc (ACHN.O)

ACHN.O on Nasdaq

10.16USD
27 Mar 2015
Change (% chg)

$0.16 (+1.60%)
Prev Close
$10.00
Open
$10.01
Day's High
$10.30
Day's Low
$9.85
Volume
2,343,666
Avg. Vol
5,382,664
52-wk High
$16.87
52-wk Low
$2.45

ACHN.O

Chart for ACHN.O

About

ACHILLION PHARMACEUTICALS, INC. is a biopharmaceutical company. The Company’s primary business is to discover, develop and commercialize treatments for infectious diseases. The Company is focused on developing short-duration combination therapies for the treatment of chronic hepatitis C virus (HCV) infection that are administere... (more)

Overall

Beta: 1.94
Market Cap(Mil.): $1,194.21
Shares Outstanding(Mil.): 117.54
Dividend: --
Yield (%): --

Financials

  ACHN.O Industry Sector
P/E (TTM): -- 137.41 40.78
EPS (TTM): -0.70 -- --
ROI: -46.51 -0.59 16.19
ROE: -46.56 -2.32 17.04
Search Stocks

US STOCKS-Wall St down on China, Greek worry; energy gains

* Indexes down: Dow 0.28 pct, S&P 0.12 pct, Nasdaq 0.02 pct (Updates to afternoon trade, commentary)

09 Feb 2015

Promising data bodes well for all-Achillion hep C treatment

- Achillion Pharmaceuticals Inc's experimental hepatitis C drug, when used with Gilead Sciences Inc's Sovaldi, eradicated signs of the virus in six weeks, the shortest duration and highest response achieved by any two-drug treatment.

09 Feb 2015

UPDATE 2-Promising data bodes well for all-Achillion hep C treatment

* Study shows Achillion's inhibitor looks best-in-class: analyst

09 Feb 2015

US STOCKS-Wall St dips on China, Greek worry; energy gains

* Indexes off: Dow 0.33 pct, S&P 0.18 pct, Nasdaq 0.24 pct (Updates to late morning trade)

09 Feb 2015

US STOCKS-Wall St dips after China data; Greek worry continues

* Qualcomm near deal with China on antitrust dispute, shares climb

09 Feb 2015

US STOCKS-Wall St to open lower on China data, Greek worry

* Futures off: Dow 105 pts, S&P 12 pts, Nasdaq 24 pts (Adds quote, updates prices)

09 Feb 2015

Achillion data shows promise of shorter-duration hep C treatment

- Data from Achillion Pharmaceuticals Inc's hepatitis C drug trials showed the company could develop a shorter-duration treatment rivaling offerings from Gilead Sciences Inc and Abbvie Inc.

22 Dec 2014

UPDATE 1-Achillion data shows promise of shorter-duration hep C treatment

* Achillion's NS5A inhibitor superior to Gilead's - analysts

22 Dec 2014

Achillion shares soar as potential treatment seen as hep C cure

Dec 22 - Achillion Pharmaceuticals Inc said it would test a combination of two of its experimental hepatitis C drugs after they showed promise against the virus in separate studies.

22 Dec 2014

Competitors

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Ford Investor Services, Inc.
$12.00
Provider: ValuEngine, Inc.
$49.00
Provider: ValuEngine, Inc.
$25.00
Provider: S&P Capital IQ Quantitative Report
$115.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks